FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients

Rachel M. Holden, David Beseau, Sarah L. Booth, Michael A. Adams, Jocelyn S. Garland, Ross A. Morton, Christine P. Collier, Rob Foley

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Fibroblast growth factor 23 (FGF-23) is elevated in patients with end-stage kidney disease and has been linked with mortality, vascular calcification, markers of bone turnover, and left ventricular hypertrophy. In this cohort study, we determined the correlates of FGF-23 (including cardiac troponin T [cTNT]) and determined its association with mortality over 3.5 years of follow-up in 103 prevalent hemodialysis patients. Mean age was 61.2 (15.5) and the mean dialysis vintage was 4.19 years (4.6). The median (interquartile range) FGF-23 was 1259 (491, 2885) RU/mL. Independent predictors (estimate standard error) of log-transformed FGF-23 concentrations included phosphorus (0.75 [0.237], P=0.002) and cardiac troponin T (1.04 [0.41], P=0.01). There were 57 deaths. In the fully adjusted model, the significant predictors of mortality included age and albumin. The independent association between FGF-23 and cTNT is a novel finding. Whether this relationship supports the possibility that a downstream effect of dysregulated phosphorous homeostasis may be enhanced cardiac remodeling requires further study.

Original languageEnglish (US)
Pages (from-to)53-58
Number of pages6
JournalHemodialysis International
Issue number1
StatePublished - Jan 2012


  • FGF-23
  • Hemodialysis
  • Mortality
  • Troponin T


Dive into the research topics of 'FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients'. Together they form a unique fingerprint.

Cite this